Evofem Biosciences, Inc. (NASDAQ: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.
Said CEO Saundra Pelletier, "Today we applaud the U.S. House of Representatives for passing The Right to Contraception Act, which would codify into law the fundamental right to safe and easy access to contraception.
"Too often, women are at the mercy of insurance companies and industry middlemen that have posted record profits, yet refuse to cover contraception or put up significant barriers to access. Providing women with their choice of contraception should not be up for debate."
Evofem is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.
The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel.
EVFM shares began Friday up 17 cents, or 20.7%, to $1.00
